Accrued Liabilities, Current of Akari Therapeutics Plc from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Akari Therapeutics Plc quarterly Accrued Liabilities, Current in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • Akari Therapeutics Plc Accrued Liabilities, Current for the quarter ending 30 Sep 2025 was $1,623,000, a 38% decline year-over-year.
Source SEC data
View on sec.gov
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Change (%)

Akari Therapeutics Plc Quarterly Accrued Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,623,000 -$982,000 -38% 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $2,468,000 -$1,934,454 -44% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $3,494,000 +$1,964,000 +128% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $3,137,000 +$1,571,000 +100% 31 Dec 2024 10-Q 13 Nov 2025 2025 Q3
Q3 2024 $2,605,000 30 Sep 2024 10-Q 19 Nov 2024 2024 Q3
Q2 2024 $4,402,454 +$2,000,470 +83% 30 Jun 2024 8-K 06 Sep 2024
Q1 2024 $1,530,000 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $1,566,000 -$472,291 -23% 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q2 2023 $2,401,984 +$991,444 +70% 30 Jun 2023 6-K 29 Sep 2023 2023 Q2
Q4 2022 $2,038,291 -$1,146,592 -36% 31 Dec 2022 8-K 06 Sep 2024
Q2 2022 $1,410,540 -$145,920 -9.4% 30 Jun 2022 6-K 27 Sep 2022 2022 Q2
Q4 2021 $3,184,883 +$1,345,177 +73% 31 Dec 2021 20-F 01 May 2023 2022 FY
Q2 2021 $1,556,460 -$384,623 -20% 30 Jun 2021 6-K 22 Sep 2021 2021 Q2
Q4 2020 $1,839,706 -$2,388,898 -56% 31 Dec 2020 20-F 16 May 2022 2021 FY
Q3 2020 $975,893 -$2,059,163 -68% 30 Sep 2020 20-F 21 Apr 2021 2020 FY
Q2 2020 $1,941,083 -$730,310 -27% 30 Jun 2020 20-F 21 Apr 2021 2020 FY
Q1 2020 $2,630,857 +$1,005,629 +62% 31 Mar 2020 20-F 21 Apr 2021 2020 FY
Q4 2019 $4,228,604 +$2,739,046 +184% 31 Dec 2019 20-F 21 Apr 2021 2020 FY
Q3 2019 $3,035,056 30 Sep 2019 20-F 21 Apr 2021 2020 FY
Q2 2019 $2,671,393 -$1,318,036 -33% 30 Jun 2019 20-F 21 Apr 2021 2020 FY
Q1 2019 $1,625,228 31 Mar 2019 20-F 21 Apr 2021 2020 FY
Q4 2018 $1,489,558 -$3,306,315 -69% 31 Dec 2018 20-F 31 Mar 2020 2019 FY
Q2 2018 $3,989,429 +$2,683,605 +206% 30 Jun 2018 6-K 27 Sep 2018 2018 Q2
Q4 2017 $4,795,873 +$2,958,226 +161% 31 Dec 2017 20-F 23 Apr 2019 2018 FY
Q2 2017 $1,305,824 +$945,145 +262% 30 Jun 2017 6-K 10 Aug 2017 2017 Q2
Q4 2016 $1,837,647 +$1,429,425 +350% 31 Dec 2016 20-F 18 Jul 2018 2017 FY
Q2 2016 $360,679 30 Jun 2016 6-K 14 Apr 2017 2016 Q2
Q1 2016 $231,905 31 Mar 2016 10-Q 12 May 2016 2016 Q1
Q4 2015 $408,222 +$365,223 +849% 31 Dec 2015 6-K 14 Apr 2017 2016 Q2
Q3 2015 $3,845,928 30 Sep 2015 10-Q 23 Nov 2015 2015 Q3
Q4 2014 $42,999 -$360,001 -89% 31 Dec 2014 10-K 23 Mar 2016 2015 FY
Q4 2013 $403,000 -$493,000 -55% 31 Dec 2013 10-K 11 Feb 2015 2014 FY
Q4 2012 $896,000 +$298,000 +50% 31 Dec 2012 20-F 24 Mar 2014 2013 FY
Q4 2011 $598,000 31 Dec 2011 20-F/A 19 Apr 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.